WELCOME TO The Biotechnology REPORT
Good Start Genetics
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
GRAIL | June 06, 2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a broad strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s therapies. The collaboration will initially focus on developing companion diagnostic tests to identify patients with high-risk, early-stage disease, with plans to embark on numerous studies across multiple indications over...
Business Wire | September 08, 2020
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the “BEAM Alliance”) as full member. The BEAM Alliance is a network of approximately 70 small and medium-sized European companies...
CELL AND GENE THERAPY
Adicet Bio, Inc. | September 06, 2022
Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022.
The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...
Labiotech | February 03, 2020
RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE